Kaleido Biosciences, Inc. has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the company's efforts.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index | CI |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.26K | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- KLDO Stock
- News Kaleido Biosciences, Inc.
- Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease Study